LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Three Factors Distinguish MODY, a Rare Diabetes, in Youth

By LabMedica International staff writers
Posted on 10 Dec 2019
Print article
Image: HbA1c Advanced Clinical Chemistry Diabetes Assay: to diagnose maturity-onset diabetes of the young (MODY), screening for at least three autoantibodies and HbA1c testing should takes place in all youth at the time of diabetes diagnosis (Photo courtesy of Beckman Coulter)
Image: HbA1c Advanced Clinical Chemistry Diabetes Assay: to diagnose maturity-onset diabetes of the young (MODY), screening for at least three autoantibodies and HbA1c testing should takes place in all youth at the time of diabetes diagnosis (Photo courtesy of Beckman Coulter)
Identifying maturity-onset diabetes of the young (MODY) in pediatric populations close to diabetes diagnosis is difficult. Misdiagnosis and unnecessary insulin treatment are common. MODY is a monogenic, dominantly inherited form of diabetes that typically arises in adolescence or young adulthood, and accounts for 1%-4% of cases of pediatric diabetes.

Among youth newly diagnosed with diabetes, a simple clinical approach, looking for moderate hyperglycemia (HbA1c less than 7.5%), asking about parental history of diabetes, and checking for autoantibodies associated with type 1 diabetes, should help determine whether young people need to be genetically screened for maturity-onset diabetes of the young (MODY).

Scientists from the Skåne University Hospital (Malmo, Sweden) and their colleagues recruited 3,933 Swedish patients aged 1–18 years, diagnosed with diabetes May 2005 to December 2010 from the national consecutive prospective cohort Better Diabetes Diagnosis. Clinical data, islet autoantibodies (GAD antibody, insulinoma antigen-2A, zinc transporter 8A, and Insulin autoantibodies [IAA]), HLA type, and C-peptide were collected at diagnosis. MODY was identified by sequencing GCK, HNF1A, and HNF4A, either through routine clinical or research testing.

The authors reported that overall, 88% (3,471) were positive for at least one of the four autoantibodies. On sequencing, none of those individuals were found to carry the MODY genes, GCK, HNF1A, or HNF4A, via routine clinical or research testing. When 303 of the autoantibody-negative patients were genetically tested, 15% (46) had MODY, resulting in a minimal prevalence of 1.2%. The others had either antibody-negative type 1 diabetes, type 2 diabetes, or other types, such as cystic fibrosis-related diabetes.

Limiting testing to the 73 islet autoantibody-negative patients with HbA1c less than 7.5% (58 mmol/mol) at diagnosis identified 36 out of 46 (78%) patients with MODY (detection rate 49%). On follow-up, the 46 patients with MODY had excellent glycemic control, with an HbA1c of 6.4% (47 mmol/mol), with 42 out of 46 (91%) patients not on insulin treatment. In an adjusted analysis, only plasma glucose and parental history of diabetes remained significant predictors of MODY.

The authors concluded that at diagnosis of pediatric diabetes, absence of all islet autoantibodies and modest hyperglycemia (HbA1c <7.5% [58 mmol/mol]) should result in testing for GCK, HNF1A, and HNF4A MODY. Testing all 12% patients negative for four islet autoantibodies is an effective strategy for not missing MODY, but will result in a lower detection rate and identifying MODY results in excellent long-term glycemic control without insulin. The study was published on November 8, 2019 in the journal Diabetes Care.

Related Links:
Skåne University Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more